OSTEOGROW
Novel Bone Morphogenetic Protein 6-Biocompatible Carrier Device for Bone Regeneration
- Description
The OSTEOGROW’s unique approach towards a new bone regeneration therapy promises to significantly improve bone repair and provide a realistic solution for patients who require partial bone replacement. While currently available solutions rely on expensive bone devices associated with side effects, OSTEOGROW is developing a therapy which uses the patient’s own blood in order to create a clot which is then injected with a special protein and placed in the spot where the new bone is needed.
- Coordinator
- Programme
- FP7
- Duration
- 72 months (January 2012 - December 2017)
- Project funding
- € 5,683,089.30
- Project partners
- 11